- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Diffuse intrinsic pontine glioma.
Displaying page 1 of 2.
| EudraCT Number: 2015-003362-84 | Sponsor Protocol Number: FSJD-DIPG-DC | Start Date*: 2016-05-18 | |||||||||||
| Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
| Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG ) | |||||||||||||
| Medical condition: Diffuse intrinsic pontine glioma (DIPG) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-002185-23 | Sponsor Protocol Number: DIPG | Start Date*: 2015-07-29 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
| Full Title: Phase 2 open label randomized study of radiotherapy, concomitant nimotuzumab and vinorelbine and re-irradiation at relapse versus radiotherapy and multiple elective radiotherapy courses with concom... | |||||||||||||
| Medical condition: diffuse intrinsic pontine glioma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003100-11 | Sponsor Protocol Number: OSAG 101-BSC-05 | Start Date*: 2006-02-14 |
| Sponsor Name:Oncoscience AG | ||
| Full Title: Phase III Study on the effectiveness of OSAG 101 (Theraloc) in newly diagnosed intrinsic pontine gliomas of children and adolescents | ||
| Medical condition: Newly diagnosed pontine glioma | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-001577-33 | Sponsor Protocol Number: D24-DIPG | Start Date*: 2016-11-03 |
| Sponsor Name:Clínica Universidad de Navarra | ||
| Full Title: Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
| Medical condition: Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-003860-11 | Sponsor Protocol Number: NL60690.029.17 | Start Date*: 2018-05-04 |
| Sponsor Name:VU University Medical Center | ||
| Full Title: 11C-erlotinib brain uptake in Diffuse Intrinsic Pontine Glioma imaged by PET | ||
| Medical condition: This study will be performed in children suffering from Diffuse Intrinsic Pontine Glioma (DIPG), who are being treated with erlotinib, and have reached steady state plasma concentrations. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-001768-60 | Sponsor Protocol Number: CNS 2007 04 | Start Date*: 2007-10-01 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas | |||||||||||||
| Medical condition: Diffuse pontine glioma in children | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002307-28 | Sponsor Protocol Number: GBMTMZ/DOX2015 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER | |||||||||||||
| Full Title: An open-label, single-center, single-arm Phase II study to evaluate safety and efficacy of doxorubicin in combination with radiotherapy, temozolomide and valproic acid in patients with glioblastoma... | |||||||||||||
| Medical condition: Glioblastoma multiforme, diffuse intrisic pontine glioma, diffuse glioma of the brain stem and spinal cord, bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004441-82 | Sponsor Protocol Number: CA209-908 | Start Date*: 2017-06-09 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies | |||||||||||||
| Medical condition: Primary central nervous system (CNS) malignancies. | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) NO (Completed) NL (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001375-16 | Sponsor Protocol Number: DIPGen | Start Date*: 2021-08-18 |
| Sponsor Name:The Children's Memorial Health Institute | ||
| Full Title: DIPGEN – Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma- DIPG) | ||
| Medical condition: diffuse intrinsic pontine glioma | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: PL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-016870-33 | Sponsor Protocol Number: CILENT-0902 | Start Date*: 2010-05-20 | |||||||||||
| Sponsor Name:Centre Oscar Lambret | |||||||||||||
| Full Title: Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study | |||||||||||||
| Medical condition: Newly diagnosed diffuse intrinsic pontine glioma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-000636-40 | Sponsor Protocol Number: PNOC022 | Start Date*: 2022-10-20 | |||||||||||||||||||||
| Sponsor Name:Pacific Pediatric Neuro-Oncology Consortium (PNOC) | |||||||||||||||||||||||
| Full Title: PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initi... | |||||||||||||||||||||||
| Medical condition: Diffuse Midline Gliomas, H3K27M mutant | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2020-004125-23 | Sponsor Protocol Number: CCRG19-002 | Start Date*: 2021-05-10 | |||||||||||||||||||||
| Sponsor Name:Antwerp University Hospital | |||||||||||||||||||||||
| Full Title: Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
| Medical condition: Childhood high-grade glioma and diffuse intrinsic pontine glioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2014-001929-32 | Sponsor Protocol Number: 2014/2126 | Start Date*: 2014-08-25 | |||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||
| Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | |||||||||||||
| Medical condition: Diffuse Intrinsic Pontine Glioma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004187-56 | Sponsor Protocol Number: HIT-HGG-2013 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2023-000604-19 | Sponsor Protocol Number: R2810-ONC-1690 | Start Date*: 2023-08-30 | |||||||||||
| Sponsor Name:Regeneron Pharmaceuticals Inc. | |||||||||||||
| Full Title: A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN281... | |||||||||||||
| Medical condition: Relapsed Solid Tumor Refractory Solid Tumor Relapsed Central Nervous System Tumor Refractory Central Nervous System Tumor Diffuse Intrinsic Pontine Glioma High Grade Glioma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002184-42 | Sponsor Protocol Number: TED12689 | Start Date*: 2016-02-19 | ||||||||||||||||
| Sponsor Name:Sanofi-aventis | ||||||||||||||||||
| Full Title: A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors Including Tumors of the Central Nervous System | ||||||||||||||||||
| Medical condition: Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-004838-37 | Sponsor Protocol Number: AloCELYVIR | Start Date*: 2021-04-19 | ||||||||||||||||
| Sponsor Name:Fundación de Investigación Biomédica Hospital Niño Jesús | ||||||||||||||||||
| Full Title: Phase IB clinical trial to assess the safety, tolerability, and preliminary efficacy of AloCELYVIR (Mesenchymal allogenic cells + ICOVIR-5) in children, adolescent and young adults with newly diagn... | ||||||||||||||||||
| Medical condition: Newly diagnosed Diffuse Intrinsic Pointine Glioma (DIPG) or Medulloblastoma in relapse/progression in children, adolescents and young adults. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-003736-77 | Sponsor Protocol Number: E7080-A001-216 | Start Date*: 2023-03-28 |
| Sponsor Name:Eisai Inc. | ||
| Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors | ||
| Medical condition: Recurrent and Refractory Solid Tumors | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
